How GSK, Chiesi Farmaceutici, Regeneron/Sanofi, Novartis, and AB Science are trying to benefit patients afflicted with Inadequately Controlled Asthma?
Delveinsight
AUGUST 13, 2020
In October 2019, GSK filed a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) seeking an additional indication for Trelegy Ellipta for the treatment of asthma in adults. Rate of severe asthma exacerbations was reduced by 23% (p=0.0076) over 52 weeks of treatment with BDP/FF/G vs BDP/FF.
40 
Let's personalize your content